On May 21, 2026 Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, reported updated positive clinical and pharmacodynamic data from its Phase 2 clinical trial of lucicebtide, a first-in-class antagonist of C/EBPβ, alone or in combination with chemoradiation standard-of-care (SOC) in patients with glioblastoma (GBM) at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29-June 2, 2026, in Chicago and online.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Despite being the most common and lethal malignant brain tumor, with more than 14,000 patients diagnosed each year in the United States, GBM remains an underserved disease, with limited progress in overall survival for patients over the last 20 years.1 C/EBPβ drives tumor growth and survival, and is a master regulator of the mesenchymal transformation in GBM, a state associated with chemotherapy resistance and aggressive disease, supporting it as a compelling therapeutic target for GBM. C/EBPβ is also recognized as regulating an immune-suppressive program in tumor-associated macrophages that contributes to tumor growth and progression. 2,3
Sapience’s ongoing Phase 2 Window-of-Opportunity study is evaluating lucicebtide alone or in combination with SOC in patients with GBM, with dosing administered before and after surgical resection. Nine patients are evaluable for analysis. As of April 27, 2026:
Patients with ndGBM treated with lucicebtide in combination with SOC achieved PFS and OS outcomes that exceed those reported in the published literature
Projected mPFS of 28.4 months meaningfully exceeds the 4.0 to 6.9-month historic benchmark range 4,5
mOS not yet reached; 6 of 9 patients remain alive beyond 22.3 months (per the cutoff date), exceeding the 14.6 to 17.0-month historic benchmark range 4,6
Lucicebtide activity is further demonstrated by on-target clinical pharmacodynamics
Target engagement confirmed via negative enrichment of C/EBPβ regulon in tumor and myeloid cells
Suppression of the mesenchymal GBM transformation observed by spatial transcriptomics analysis
Lucicebtide is well tolerated, with no DLTs or related SAEs observed
"The ASCO (Free ASCO Whitepaper) 2026 lucicebtide dataset continues to reinforce our conviction in the strength of this program," said Barry Kappel, Ph.D., Sapience’s Chief Executive Officer. "The maturing results show durable progression free and overall survival improvements, and clearly position lucicebtide as a promising, well‑tolerated therapy with the potential to elevate the standard of care in GBM. We are eager to advance this program to bring meaningful progress to patients and families affected by this devastating disease."
Details of the presentation are as follows:
Title: "Lucicebtide (ST101) Plus Chemoradiation in Newly Diagnosed GBM Patients: Efficacy, Pharmacodynamics, and Safety in Phase 2 Window-of-Opportunity Study"
Session Title: Poster Session – Central Nervous System Tumors
Poster Board: 444
Date and Time: Monday, June 1, 2026, 1:30 PM-4:30 PM CDT
More information can be found on the ASCO (Free ASCO Whitepaper) Annual Meeting 2026 website.
About Lucicebtide (formerly known as ST101)
Lucicebtide is a first-in-class peptide antagonist of CCAAT/enhancer-binding protein β (C/EBPβ), a transcription factor that drives tumor aggressiveness, immune evasion and therapy resistance in GBM. Lucicebtide has been studied in 125 patients and is observed to be safe, well-tolerated and clinically active both as a monotherapy in recurrent GBM (rGBM) and in combination with SOC chemoradiation in ndGBM. Lucicebtide was designed with a cell-penetration domain that enables it to cross the blood-brain barrier and enter the nucleus of cells, and a binding domain that specifically interacts with C/EBPβ, preventing it from dimerizing to an active state and driving it to be degraded by the cell’s own machinery.7 Lucicebtide has been granted Fast Track designation for rGBM from the U.S. Food and Drug Administration (U.S. FDA) and orphan designations for glioma from the U.S. FDA and the European Commission.
About the Lucicebtide Window-of-Opportunity Study
Lucicebtide has completed the main portion of a Phase 2 dose expansion study in rGBM (NCT04478279). An ongoing Window-of-Opportunity sub-study is evaluating lucicebtide in combination with radiation and temozolomide in patients with newly diagnosed GBM (ndGBM) and as a monotherapy in patients with rGBM, with patients receiving lucicebtide before and after surgical resection in both cohorts.
(Press release, Sapience Therapeutics, MAY 21, 2026, View Source [SID1234665964])